568 related articles for article (PubMed ID: 11050808)
1. [Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
Cersósimo MG; Scorticati MC; Micheli FE
Medicina (B Aires); 2000; 60(3):321-5. PubMed ID: 11050808
[TBL] [Abstract][Full Text] [Related]
2. Long-term antidyskinetic efficacy of amantadine in Parkinson's disease.
Wolf E; Seppi K; Katzenschlager R; Hochschorner G; Ransmayr G; Schwingenschuh P; Ott E; Kloiber I; Haubenberger D; Auff E; Poewe W
Mov Disord; 2010 Jul; 25(10):1357-63. PubMed ID: 20198649
[TBL] [Abstract][Full Text] [Related]
3. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
[TBL] [Abstract][Full Text] [Related]
4. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease.
Zesiewicz TA; Sullivan KL; Maldonado JL; Tatum WO; Hauser RA
Mov Disord; 2005 Sep; 20(9):1205-9. PubMed ID: 15954135
[TBL] [Abstract][Full Text] [Related]
5. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
[TBL] [Abstract][Full Text] [Related]
6. Levodopa "drug holiday" with amantadine infusions as a treatment of complications in Parkinson's disease.
Koziorowski D; Friedman A
Mov Disord; 2007 May; 22(7):1033-6. PubMed ID: 17370308
[TBL] [Abstract][Full Text] [Related]
7. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study.
Merello M; Nouzeilles MI; Cammarota A; Leiguarda R
Clin Neuropharmacol; 1999; 22(5):273-6. PubMed ID: 10516877
[TBL] [Abstract][Full Text] [Related]
8. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
Blanchet PJ; Konitsiotis S; Chase TN
Mov Disord; 1998 Sep; 13(5):798-802. PubMed ID: 9756148
[TBL] [Abstract][Full Text] [Related]
9. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE
Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of pallidotomy versus medical therapy for Parkinson's disease.
Vitek JL; Bakay RA; Freeman A; Evatt M; Green J; McDonald W; Haber M; Barnhart H; Wahlay N; Triche S; Mewes K; Chockkan V; Zhang JY; DeLong MR
Ann Neurol; 2003 May; 53(5):558-69. PubMed ID: 12730989
[TBL] [Abstract][Full Text] [Related]
11. Dropped head associated with amantadine in Parkinson disease.
Kataoka H; Ueno S
Clin Neuropharmacol; 2011; 34(1):48-9. PubMed ID: 21242745
[TBL] [Abstract][Full Text] [Related]
12. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
da Silva-Júnior FP; Braga-Neto P; Sueli Monte F; de Bruin VM
Parkinsonism Relat Disord; 2005 Nov; 11(7):449-52. PubMed ID: 16154788
[TBL] [Abstract][Full Text] [Related]
13. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.
Berg D; Godau J; Trenkwalder C; Eggert K; Csoti I; Storch A; Huber H; Morelli-Canelo M; Stamelou M; Ries V; Wolz M; Schneider C; Di Paolo T; Gasparini F; Hariry S; Vandemeulebroecke M; Abi-Saab W; Cooke K; Johns D; Gomez-Mancilla B
Mov Disord; 2011 Jun; 26(7):1243-50. PubMed ID: 21484867
[TBL] [Abstract][Full Text] [Related]
14. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Verhagen Metman L; Del Dotto P; van den Munckhof P; Fang J; Mouradian MM; Chase TN
Neurology; 1998 May; 50(5):1323-6. PubMed ID: 9595981
[TBL] [Abstract][Full Text] [Related]
15. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.
Del Dotto P; Pavese N; Gambaccini G; Bernardini S; Metman LV; Chase TN; Bonuccelli U
Mov Disord; 2001 May; 16(3):515-20. PubMed ID: 11391748
[TBL] [Abstract][Full Text] [Related]
16. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
17. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
Maurel F; Lilliu H; Le Pen C
Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
[TBL] [Abstract][Full Text] [Related]
18. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study.
Snow BJ; Macdonald L; Mcauley D; Wallis W
Clin Neuropharmacol; 2000; 23(2):82-5. PubMed ID: 10803797
[TBL] [Abstract][Full Text] [Related]
19. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.
Van Gerpen JA; Kumar N; Bower JH; Weigand S; Ahlskog JE
Arch Neurol; 2006 Feb; 63(2):205-9. PubMed ID: 16476808
[TBL] [Abstract][Full Text] [Related]
20. Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease.
Filipović SR; Rothwell JC; van de Warrenburg BP; Bhatia K
Mov Disord; 2009 Jan; 24(2):246-53. PubMed ID: 18951540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]